Coherus BioSciences (CHRS) Competitors $0.75 -0.03 (-3.37%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. CGEM, ETON, ALT, SANA, MGTX, MAZE, SIGA, ZVRA, SAGE, and AMLXShould you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Cullinan Therapeutics (CGEM), Eton Pharmaceuticals (ETON), Altimmune (ALT), Sana Biotechnology (SANA), MeiraGTx (MGTX), Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Coherus BioSciences vs. Cullinan Therapeutics Eton Pharmaceuticals Altimmune Sana Biotechnology MeiraGTx Maze Therapeutics SIGA Technologies Zevra Therapeutics Sage Therapeutics Amylyx Pharmaceuticals Coherus BioSciences (NASDAQ:CHRS) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment. Do analysts rate CHRS or CGEM? Coherus BioSciences presently has a consensus target price of $4.68, suggesting a potential upside of 504.22%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 305.58%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than Cullinan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CHRS or CGEM? In the previous week, Coherus BioSciences and Coherus BioSciences both had 4 articles in the media. Cullinan Therapeutics' average media sentiment score of 1.10 beat Coherus BioSciences' score of 0.69 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in CHRS or CGEM? Coherus BioSciences received 403 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 83.93% of users gave Cullinan Therapeutics an outperform vote while only 64.94% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformCoherus BioSciencesOutperform Votes45064.94% Underperform Votes24335.06% Cullinan TherapeuticsOutperform Votes4783.93% Underperform Votes916.07% Is CHRS or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coherus BioSciences-0.15% N/A -24.44% Cullinan Therapeutics N/A -26.54%-25.32% Which has more risk and volatility, CHRS or CGEM? Coherus BioSciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Which has better valuation & earnings, CHRS or CGEM? Cullinan Therapeutics has lower revenue, but higher earnings than Coherus BioSciences. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus BioSciences$272.25M0.33-$237.89M-$1.13-0.69Cullinan TherapeuticsN/AN/A-$153.16M-$2.91-2.71 Do insiders & institutionals believe in CHRS or CGEM? 72.8% of Coherus BioSciences shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.1% of Coherus BioSciences shares are held by company insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryCoherus BioSciences and Cullinan Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.86M$2.93B$5.33B$8.39BDividend YieldN/A1.64%5.21%4.11%P/E Ratio-9.6931.1826.7119.71Price / Sales0.33398.78386.46120.65Price / CashN/A168.6838.2534.62Price / Book-0.453.236.774.50Net Income-$237.89M-$72.35M$3.23B$248.22M7 Day Performance1.85%2.49%0.48%-0.78%1 Month Performance-30.17%2.45%9.10%11.53%1 Year Performance-61.44%-24.98%18.56%8.99% Coherus BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus BioSciences3.6716 of 5 stars$0.75-3.4%$4.68+525.3%-63.3%$86.83M$272.25M-9.36330Analyst DowngradeGap DownCGEMCullinan Therapeutics2.3873 of 5 stars$7.91+4.9%$32.00+304.6%-65.9%$466.81MN/A-2.7930ETONEton Pharmaceuticals2.3835 of 5 stars$17.35+3.3%$27.67+59.5%+453.3%$465.29M$39.01M-78.8620Positive NewsHigh Trading VolumeALTAltimmune2.4726 of 5 stars$6.01+7.5%$20.20+236.1%-26.9%$462.85M$20,000.00-3.8850Analyst UpgradeGap UpSANASana Biotechnology2.4303 of 5 stars$2.00+9.9%$10.80+440.0%-75.8%$450.95MN/A-1.43380Gap DownHigh Trading VolumeMGTXMeiraGTx4.5668 of 5 stars$5.62+3.7%$24.50+335.9%-10.6%$449.33M$33.28M-4.64300Analyst DowngradeMAZEMaze TherapeuticsN/A$10.13+5.3%$25.67+153.4%N/A$443.65M$167.50M0.00121Gap UpSIGASIGA Technologies1.1589 of 5 stars$5.94+4.9%N/A-21.9%$424.36M$138.72M4.9540Positive NewsZVRAZevra Therapeutics3.2331 of 5 stars$7.75-1.5%$22.29+187.6%+85.1%$423.76M$23.61M-3.9320Analyst UpgradeSAGESage Therapeutics3.8332 of 5 stars$6.75+2.9%$8.81+30.6%-45.4%$422.69M$47.40M-1.02690Gap UpAMLXAmylyx Pharmaceuticals3.44 of 5 stars$4.60-0.2%$9.67+110.1%+192.9%$409.79M$-1,272,000.00-1.20200 Related Companies and Tools Related Companies Cullinan Therapeutics Alternatives Eton Pharmaceuticals Alternatives Altimmune Alternatives Sana Biotechnology Alternatives MeiraGTx Alternatives Maze Therapeutics Alternatives SIGA Technologies Alternatives Zevra Therapeutics Alternatives Sage Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRS Stock Free CHRS Stock Alerts